Marshall Wace, LLP Gritstone Bio, Inc. Transaction History

Marshall Wace, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $374,281 - $657,189	175,719 Added 71.34%	422,045 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $461,580 - $833,823	212,710 Added 632.76%	246,326 $849,000
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $197,828 - $381,985	-80,418 Reduced 70.52%	33,616 $87,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $354,617 - $869,514	-200,349 Reduced 63.73%	114,034 $276,000
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $1.27 Million - $3.83 Million	314,383 New	314,383 $1.3 Million
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $237,168 - $371,184	-27,074 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $398,766 - $842,323	-62,210 Reduced 69.68%	27,074 $292,000
Q2 2021 Aug 13, 2021	SELL	$8.13 - $10.2 $63,145 - $79,223	-7,767 Reduced 8.0%	89,284 $815,000
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $394,997 - $2.63 Million	97,051 New	97,051 $915,000
Q2 2020 Aug 13, 2020	SELL	$5.69 - $8.17 $26,680 - $38,309	-4,689 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.47 - $11.3 $25,648 - $52,985	4,689 New	4,689 $27,000
Q4 2019 Feb 14, 2020	SELL	$7.07 - $11.61 $1.06 Million - $1.74 Million	-149,643 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $1.04 Million - $1.51 Million	-123,191 Reduced 45.15%	149,643 $1.29 Million
Q2 2019 Aug 14, 2019	BUY	$9.2 - $15.7 $1.52 Million - $2.59 Million	164,815 Added 152.58%	272,834 $3.04 Million
Q1 2019 May 14, 2019	BUY	$9.97 - $18.96 $1.08 Million - $2.05 Million	108,019 New	108,019 $1.44 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.